{{Rsnum
|rsid=2230739
|Gene=ADCY9
|Chromosome=16
|position=3983435
|Orientation=minus
|GMAF=0.2796
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ADCY9
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 39.8 | 47.8 | 12.4
| HCB | 34.3 | 50.4 | 15.3
| JPT | 41.1 | 46.4 | 12.5
| YRI | 75.5 | 24.5 | 0.0
| ASW | 75.4 | 24.6 | 0.0
| CHB | 34.3 | 50.4 | 15.3
| CHD | 32.1 | 45.9 | 22.0
| GIH | 46.5 | 40.6 | 12.9
| LWK | 94.5 | 4.5 | 0.9
| MEX | 55.2 | 44.8 | 0.0
| MKK | 82.1 | 16.7 | 1.3
| TSI | 39.2 | 48.0 | 12.7
| HapMapRevision=28
}}

{{omim
|desc=ADENYLATE CYCLASE 9; ADCY9
|id=603302
|rsnum=2230739
}}

{{PMID Auto
|PMID=20386734
|Title=Further evidence supporting a role for gs signal transduction in severe malaria pathogenesis.
|OA=1
}}

{{PMID Auto
|PMID=20459687
|Title=Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring.
|OA=1
}}

{{GET Evidence
|gene=ADCY9
|aa_change=Ile772Met
|aa_change_short=I772M
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2230739
|overall_frequency_n=2781
|overall_frequency_d=10758
|overall_frequency=0.258505
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=34
|n_articles=0
|n_articles_annotated=0
|nblosum100=-1
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}